Preliminary study of the fibrin structure in hypertensive, dyslipidemic and type 2 diabetic patients

Investigacion Clinica

Volumn 51, Issue 3, 2010, Pages 315-324

  Marchi Cappelletti, Rita ^a   Suárez Nieto, Nuris ^a  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

Compaction; Dyslipidemia; Fibrin lysis; Fibrin structure; Hypertension; Permeation; Polymerization; Type 2 diabetes

Indexed keywords

CHOLESTEROL; FIBRIN;

ADULT; ARTICLE; BLOOD CLOTTING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FEMALE; FIBRIN POLYMERIZATION; FIBRINOLYSIS; GLYCATION; HUMAN; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POROSITY; SYSTOLIC BLOOD PRESSURE;

DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; FIBRIN; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78650445792     PISSN: 05355133     EISSN: 05355133     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126.
2. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104:365-372. (Pubitemid 32666962)
3. Frishman WH. Biologic markers as predictors of cardiovascular disease. Am J Med 1998; 104 (6A):18S-27S.
4. Semple RK, Sleigh A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, Vottero A, Kanabar D, Charlton-Menys V, Durrington P, Soos MA, Carpenter TA, Lomas DJ, Cochran EK, Gorden P, O'Rahilly S, Savage DB. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest 2009; 119:315-322.
5. Pausova Z, Gaudet D, Gossard F, Bernard M, Kaldunski ML, Jomphe M, Tremblay J, Hudson TJ, Bouchard G, Kotchen TA, Cowley AW, Hamet P. Genome-wide scan for linkage to obesity-associated hypertension in French Canadians. Hypertension 2005; 46:1280-1285. (Pubitemid 43189724)
6. Dielis AW, Smid M, Spronk HM, Hamulyak K, Kroon AA, ten Cate H, de Leeuw PW. The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems. Hypertension 2005; 46:1236-1242.
7. Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, Cline GW, Befroy D, Zemany L, Kahn BB, Papademetris X, Rothman DL, Shulman GI. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci USA 2007; 104:12587-12594.
8. Adiels M, Oloffson S, Taskinen MR, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28:1225-1236.
9. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA 1979; 241:2035-2038. (Pubitemid 9228506)
10. Carr ME. Diabetes mellitus: a hypercoagulable state: J Diabetes Complications 2001; 15:44-54.
11. Sobel BE. Effects of glycemic control and other determinants on vascular disease in type 2 diabetes. Am J Med 2002; 113 (Suppl. 6A):12S-22S.
12. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB, Wilson PW. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283:221-228. (Pubitemid 30039222)
13. Stegenga ME, van der Crabben SN, Levi M, de Vos AF, Tanck MW, Sauerwein HP, van der Poll T. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 2006; 55:1807-1812. (Pubitemid 44324136)
14. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003; 89:601-609.
15. Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, Weisel JW. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20:1354-1361. (Pubitemid 30262939)
16. Fatah K, Hamsten A, Blombäck B, Blombäck M. Fibrin gel network characteristics and coronary heart disease: relation to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68:130-135.
17. Ingram GI. The determination of plasma fibrinogen by the clot weight method. Biochem J 1952; 51:583-585.
18. Marchi R, Meyer M, de Bosch N, Soria J, Arocha-Piñango CL, John W. Weisel: Biophysical characterization of fibrinogen Caracas I with an Aα-chain truncation at Aα 466 Ser. Identification of the mutation and biophysical characterization of properties of clots from plasma and purified fibrinogen. Blood Coagul Fibrinolysis 2004; 15:285-293.
19. Dhall TZ, Bryce WA, Dhall DP: Effects of dextran on the molecular structure and tensile behavior of human fibrinogen. Thromb Haemost 1976; 35:737-745.
20. Nair CH, Shats EA. Compaction as a method to characterize fibrin network structure: kinetic studies and relationship to crosslinking. Thromb Res 1997; 88: 381-387.
21. Ganda OP, Arkin CF. Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes. Diabetes Care 1992; 15:1245-1250.
22. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987; 113:1006-1010.
23. Nair CH, Azhar A, Wilson JD, Dhall DP. Studies on fibrin network structure in human plasma. Part II-Clinical application: diabetes and antidiabetic drugs. Thromb Res 1991; 64: 477-485.
24. Pieters M, Covic N, Loots du T, van der Westhuizen FH, van Zyl DG, Rheeder P, Jerling JC, Weisel JW. The effect of glycaemic control on fibrin network structure of type 2 diabetic subjects. Thromb Haemost 2006; 96:623-629.
25. Dunn EJ, Philippou H, Ariëns RA, Grant PJ. Molecular mechanisms involved in the resistance of fibrin clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006; 49:1071-1080.
26. Carr ME. Fibrin formed in plasma is composed of fibers more massive than those formed from purified fibrinogen. Thromb Haemost 1988; 59:535-539.
27. Krantz S, Lober M, Thiele M, Teuscher E. Properties of in vitro nonenzymatically glycated plasma fibrinogens. Exp Clin Endocrinol 1987; 90:37-45.
28. Mirshahi M, Soria J, Soria C, Bertrand O, Mirshahi M, Basdevant A. Glycosylation of human fibrinogen and fibrin in vitro. Its consequences on the properties of fibrin(ogen). Thromb Res 1987; 48:279-289.
29. Henschen-Edman AH. Fibrinogen non-inherited heterogeneity and its relationship to function in health and disease. Ann NY Acad Sci 2001; 936:580-593.
30. Hoffman M. Alterations of fibrinogen in human disease: Cardiovasc Hematol Agents Med Chem 2008; 6:206-211.
31. Dunn EJ, Ariëns RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 2005; 48:1198-1206. (Pubitemid 40909657)
32. de la Peña-Diaz A, Izaguirre-Avila R, Anglés-Cano E. Lipoprotein Lp(a) and atherothrombotic disease. Arch Med Res 2000; 31:353-359.
33. Rouy D, Koschinsky ML, Fleury V, Chapman J, Anglés-Cano E. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments. Biochemistry 1992; 31:6333-6339.
34. Weisel JW, Litvinov RI. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem 2008; 6:161-180.
35. Ryan EA, Mockros LF, Weisel JW, Lorand L. Structural origins of fibrin clot rheology. Biophys J 1999; 77:2813-2826. (Pubitemid 29519524)